Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
260000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Substantial exercise of Series 3 stock acquisition rights issued through a third-party allotment (with exercise price adjustment and exercise suspension provisions)
発行・処分する株式数
260,000 new shares; 0 transferred treasury shares
Intended allottee
EVO FUND (allottee at the time of issuance)
Terms of the stock acquisition rights
Exercise price
¥477 (details of the adjustment provisions and the adjustment floor: not disclosed)
Number of Stock Acquisition Rights
Total issued: 12,000; exercised since the previous disclosure: 2,600; unexercised as of the previous disclosure: 6,400; currently unexercised: 3,800
Most recent equity financing
Timing 29 December 2025 / Type Issuance of Series 3 stock acquisition rights / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Substantial exercise of Series 3 stock acquisition rights issued through a third-party allotment (with exercise price adjustment and exercise suspension provisions) |
| Number of shares to be issued or disposed of | 260,000 new shares; 0 transferred treasury shares |
| Intended allottee | EVO FUND (allottee at the time of issuance) |
| Total number of issued shares | 14,815,200 shares (as of the end of the month preceding the subject month, including 80 treasury shares) → Not disclosed |
| Exercise price | ¥477 (details of the adjustment provisions and the adjustment floor: not disclosed) |
| Number of Stock Acquisition Rights | Total issued: 12,000; exercised since the previous disclosure: 2,600; unexercised as of the previous disclosure: 6,400; currently unexercised: 3,800 |
| Most recent equity financing | Timing 29 December 2025 / Type Issuance of Series 3 stock acquisition rights / Amount Not disclosed |
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The status of the substantial exercise was disclosed because a substantial number of rights had been exercised.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.